Global Cancer Vaccine Partnering 2010-2015: Deal Trends, Players, Financials and Forecasts

Jul 13, 2015, 12:38 ET from Research and Markets

DUBLIN, July 08, 2015 /PRNewswire/ --

Research and Markets(http://www.researchandmarkets.com/research/xq558m/global_cancer) has announced the addition of the "Global Cancer Vaccine Partnering 2010-2015: Deal trends, players, financials and forecasts" report to their offering.

The Global Cancer Vaccine Partnering 2010-2015 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report provides details of the latest cancer vaccine agreements announced in the healthcare sectors covering the following diagnostics types including adjuvant.

  • Attenuated vaccine
  • Subunit vaccine
  • Toxoid vaccine
  • Conjugate vaccine
  • Inactivated vaccine
  • DNA vaccine
  • Recombinant vector vaccine

Report scope:

Global Cancer Vaccine Partnering 2010-2015 includes:

  • Trends in cancer vaccine dealmaking in the biopharma industry since 2010.
  • Analysis of cancer vaccine deal structure.
  • Access to headline, upfront, milestone and royalty data.
  • Access to over 150 cancer vaccine deal records.
  • The leading cancer vaccine deals by value since 2010.

In Global Cancer Vaccine Partnering 2010-2015 , the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target

Key Topics Covered:

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in cancer vaccine dealmaking

Chapter 3 Average financial deal terms for cancer vaccine partnering

Chapter 4 Leading cancer vaccine deals

Chapter 5 Cancer vaccine dealmaking contracts directory

Chapter 6 Cancer vaccine dealmaking by specific therapy type

Chapter 7 Cancer vaccine dealmaking by specific technology type

Chapter 8 Future trends and companies in cancer vaccine deal making

Chapter 9 Partnering resource center

For more information visit http://www.researchandmarkets.com/research/xq558m/global_cancer

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com